Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:MRK NASDAQ:SMMT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMRKMerck & Co., Inc.$120.91-2.5%$119.12$76.66▼$130.29$298.62B0.1910.98 million shs5.38 million shsSMMTSummit Therapeutics$15.42+0.8%$15.68$12.55▼$30.98$11.97B-1.263.98 million shs2.14 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMRKMerck & Co., Inc.+0.17%-2.25%+4.10%+3.33%+48.69%SMMTSummit Therapeutics+0.33%-3.95%+9.21%-26.62%-38.80%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMRKMerck & Co., Inc.$120.91-2.5%$119.12$76.66▼$130.29$298.62B0.1910.98 million shs5.38 million shsSMMTSummit Therapeutics$15.42+0.8%$15.68$12.55▼$30.98$11.97B-1.263.98 million shs2.14 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMRKMerck & Co., Inc.+0.17%-2.25%+4.10%+3.33%+48.69%SMMTSummit Therapeutics+0.33%-3.95%+9.21%-26.62%-38.80%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMRKMerck & Co., Inc. 2.70Moderate Buy$133.9410.78% UpsideSMMTSummit Therapeutics 2.44Hold$26.9774.89% UpsideCurrent Analyst Ratings BreakdownLatest SMMT and MRK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/13/2026MRKMerck & Co., Inc. JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$135.00 ➝ $140.007/13/2026MRKMerck & Co., Inc. BMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$135.00 ➝ $142.007/13/2026MRKMerck & Co., Inc. GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$140.00 ➝ $145.007/9/2026MRKMerck & Co., Inc. Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$112.00 ➝ $113.007/8/2026MRKMerck & Co., Inc. Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$142.007/8/2026MRKMerck & Co., Inc. Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$145.00 ➝ $150.007/6/2026MRKMerck & Co., Inc. Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$120.006/30/2026MRKMerck & Co., Inc. Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$130.00 ➝ $141.006/30/2026MRKMerck & Co., Inc. ScotiabankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Outperform$136.00 ➝ $155.006/24/2026MRKMerck & Co., Inc. CICC ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$138.006/1/2026SMMTSummit Therapeutics KeyCorpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight(Data available from 7/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMRKMerck & Co., Inc.$65.01B4.59$11.18 per share10.81$21.22 per share5.70SMMTSummit TherapeuticsN/AN/AN/AN/A$0.85 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMRKMerck & Co., Inc.$18.25B$3.5534.0612.212.6513.59%27.55%10.73%8/4/2026 (Estimated)SMMTSummit Therapeutics-$1.08B-$1.60N/AN/AN/AN/A-291.24%-243.07%8/10/2026 (Estimated)Latest SMMT and MRK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/10/2026Q2 2026SMMTSummit Therapeutics-$0.26N/AN/AN/A$0.11 millionN/A8/4/2026Q2 2026MRKMerck & Co., Inc.$2.15N/AN/AN/A$16.40 billionN/A5/1/2026Q1 2026SMMTSummit Therapeutics-$0.2692-$0.24+$0.0292-$0.24$0.05 millionN/A4/30/2026Q1 2026MRKMerck & Co., Inc.-$1.47-$1.28+$0.19-$1.72$15.85 billion$16.29 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthMRKMerck & Co., Inc.$3.402.81%+5.75%95.77%14 YearsSMMTSummit TherapeuticsN/AN/AN/AN/AN/ALatest SMMT and MRK DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/26/2026MRKMerck & Co., Inc.quarterly$0.852.96%6/15/20266/15/20267/8/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMRKMerck & Co., Inc.1.021.301.06SMMTSummit TherapeuticsN/A7.417.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMRKMerck & Co., Inc.76.07%SMMTSummit Therapeutics4.61%Insider OwnershipCompanyInsider OwnershipMRKMerck & Co., Inc.0.17%SMMTSummit Therapeutics83.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMRKMerck & Co., Inc.75,0002.47 billion2.47 billionOptionableSMMTSummit Therapeutics110776.16 million128.07 millionOptionableSMMT and MRK HeadlinesRecent News About These Companies119,655 Shares in Summit Therapeutics PLC $SMMT Bought by Y Intercept Hong Kong LtdJuly 9, 2026 | marketbeat.comSummit Therapeutics PLC (NASDAQ:SMMT) Given Average Rating of "Hold" by BrokeragesJuly 9, 2026 | marketbeat.comSMMT Stock Price PredictionJuly 4, 2026 | 247wallst.comSummit Therapeutics (NASDAQ:SMMT) Stock Rating Upgraded by Wall Street ZenJuly 4, 2026 | americanbankingnews.comHsbc Holdings PLC Buys New Shares in Summit Therapeutics PLC $SMMTJuly 1, 2026 | marketbeat.comSummit Therapeutics: High-Volatility, Catalyst-Driven Binary BetJune 22, 2026 | seekingalpha.comSummit Therapeutics PLC $SMMT Shares Bought by Baker BROS. Advisors LPJune 18, 2026 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) CEO Mahkam Zanganeh Purchases 3,810,000 SharesJune 13, 2026 | insidertrades.comWhy is SMMT stock tumbling today?June 10, 2026 | msn.comSummit Therapeutics Announces Proposed Public Offering of Common StockJune 9, 2026 | businesswire.comSummit Therapeutics Inc. (SMMT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 8, 2026 | seekingalpha.comMizuho Strategist: Healthcare Is Now a Value Sector as Pharma Stocks Underperform TechJune 7, 2026 | 247wallst.comThe Era of the One-Size-Fits-All Cancer Drug Is EndingJune 6, 2026 | wsj.comSummit Therapeutics (SMMT) Reveals Phase II AK112-206 Trial DataJune 5, 2026 | finance.yahoo.comSummit Therapeutics (NASDAQ:SMMT) CFO Manmeet Singh Soni Buys 50,000 SharesJune 5, 2026 | insidertrades.comSummit Therapeutics to Participate in the 47th Annual Goldman Sachs Global Healthcare ConferenceJune 4, 2026 | businesswire.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Summit Therapeutics (SMMT), Oculis Holding (OCS) and Cogent Biosciences (COGT)June 4, 2026 | theglobeandmail.comAssessing Summit Therapeutics (SMMT) Valuation After A Mixed Share Price And Long Term Return ProfileJune 4, 2026 | finance.yahoo.comAll You Need to Know About Summit Therapeutics (SMMT) Rating Upgrade to BuyJune 4, 2026 | zacks.comSummit Therapeutics Inc. (SMMT) Discusses Plenary Session Updates and Recent Clinical Data Following Major Oncology Congress - SlideshowJune 3, 2026 | seekingalpha.comCantor Fitzgerald Maintains Overweight Rating on Summit Therapeutics (SMMT) Amid Mixed Clinical DevelopmentsJune 2, 2026 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSMMT and MRK Company DescriptionsMerck & Co., Inc. NYSE:MRK$120.91 -3.12 (-2.52%) Closing price 03:59 PM EasternExtended Trading$120.77 -0.14 (-0.11%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.Summit Therapeutics NASDAQ:SMMT$15.42 +0.12 (+0.80%) Closing price 03:59 PM EasternExtended Trading$15.46 +0.04 (+0.27%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Fastenal’s Latest Drop Could Be Its Biggest Opportunity Yet 3 Overlooked Energy ETFs Delivering Strong Returns and Income 3 Space Stocks That Could Outshine SpaceX After Its IPO 3 Energy Stocks Racing to Fix AI's Power Problem JPMorgan’s Q2 Strength Gives the Stock Rally New Support No Space For Panic: T-Mobile Shrugs Off The Starlink Threat Prepare for the Next Wave of Factory Automation With These 3 Standout Names Wedbush Pounds the Table—Buy Sandisk Before August 5 Earnings Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
